Business Segments Shanghai RAAS Blood Products Co., Ltd.
Equities
002252
CNE100000C31
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.700 CNY | -0.70% |
|
-0.70% | -10.09% |
| Mar. 27 | RAAS Blood Products' 2025 Profit Slides 28%, Revenue Falls 10% | MT |
| Mar. 26 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Unallocated Other Operations | 3.01M | - | - | - | - | |||||
Chinese Medicine Products and Food | - | - | - | - | - | |||||
Biological Products | ||||||||||
Production and Sale of Blood Products | 4.28B | 6.57B | 7.96B | 8.18B | - | |||||
Total Assets | - | 30.46B | 31.93B | 33.63B | - | |||||
Interest Expense | - | -263K | -120K | -225K | - | |||||
Income Tax Expense | - | 401M | 427M | 426M | - | |||||
CAPEX | - | -226M | -451M | -407M | - | |||||
EBT | - | 2.27B | 2.2B | 2.62B | - | |||||
D&A | - | 182M | 159M | 201M | - | |||||
Operating Income | - | 2.28B | 2.23B | 2.68B | - | |||||
Net Income | - | 1.88B | 1.78B | 2.19B | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Southwest Region | 202M | 323M | 516M | 484M | - | |||||
Southern China | 1.03B | 1.59B | 1.86B | 1.69B | - | |||||
Northern China | 897M | 1.54B | 1.93B | 2.1B | - | |||||
Northwestern Region | 167M | 280M | 364M | 470M | - | |||||
Northeast China Region | 172M | 252M | 298M | 384M | - | |||||
Export | 273M | 169M | 22.81M | 56.69M | - | |||||
East China | 1.54B | 2.41B | 2.98B | 2.99B | - |
Select your edition
All financial news and data tailored to specific country editions
